Dr. Kashif Hanif is a Principal Scientist in the Department of Pharmacology at CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh. He received his postgraduate degree (1998-2000) from Jamia Hamdard and completed his Ph.D. (2001-2006) from CSIR-Institute of Genomics and Integrative Biology, Delhi. He has been a faculty member at CSIR-Central Drug Research Institute since 2006. His primary research interest revolves around the patho-physiology of Pulmonary Hypertension (PH), which is quite common at high altitude and in lung disorders, especially in women. He developed the rodent model of PH and standardized techniques to study right ventricular pressure and pulmonary vasorelaxation. Over the past decade, he has explored the role of Poly (ADP-Ribose) Polymerase-1, Fatty Acid Synthase, Mitogen Activated Protein Kinase -2 (MK2) and estrogen receptors in PH.

Dr. Hanif was awarded the Dr. DN Prasad Memorial Oration Award, Indian Council of Medical Research in 2019 and Prof. Suresh C Tyagi Award, Indian Academy of Cardiovascular Research in 2017 for his work in PH. He has received six competitive research grants from Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), and the Central Council for Research in Unani Medicine (CCRUM).

During his Fulbright-Nehru Academic and Professional Excellence fellowship, Dr. Hanif aims to understand right ventricle hypertrophy, a common problem of PH in lung diseases in women. Therefore, he is developing a rodent model of right ventricle hypertrophy by pulmonary artery banding (PAB). He is further exploring the role of estrogen receptors in right ventricle hypertrophy by using Raloxifene, a selective estrogen receptor modulator (SERM). This approach will help to clinically repurpose SERMs for cardio-pulmonary complications in women.